Aridis Pharma Says Phase 2a Study Of AR-501 In Cystic Fibrosis Meets Endpoints
Aridis Pharmaceuticals, Inc. (ARDS) announced Monday preliminary top-line results from the randomized, double blinded, placebo-controlled Phase 2a study of AR-501, which evaluated the safety and pharmacokinetics of three ascending doses of AR-501 administered as an inhaled aerosol in cystic fibrosis (CF) patients with confirmed Pseudomonas aeruginosa bacterial and other potential infections.
Source: rttnews.com